[go: up one dir, main page]

WO2009072334A1 - 製剤用核粒子 - Google Patents

製剤用核粒子 Download PDF

Info

Publication number
WO2009072334A1
WO2009072334A1 PCT/JP2008/066159 JP2008066159W WO2009072334A1 WO 2009072334 A1 WO2009072334 A1 WO 2009072334A1 JP 2008066159 W JP2008066159 W JP 2008066159W WO 2009072334 A1 WO2009072334 A1 WO 2009072334A1
Authority
WO
WIPO (PCT)
Prior art keywords
core particle
pharmaceutical preparation
inorganic material
active ingredient
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066159
Other languages
English (en)
French (fr)
Inventor
Masashi Konishi
Shouichi Oonishi
Akira Ookubo
Masashi Yunoki
Ariumi Kawamoto
Kanako Hattori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tomita Pharmaceutical Co Ltd
Original Assignee
Tomita Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tomita Pharmaceutical Co Ltd filed Critical Tomita Pharmaceutical Co Ltd
Priority to EP08857578.2A priority Critical patent/EP2223702B1/en
Priority to US12/745,851 priority patent/US9149434B2/en
Priority to JP2009544605A priority patent/JPWO2009072334A1/ja
Publication of WO2009072334A1 publication Critical patent/WO2009072334A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

核粒子として要求される特性を備えつつ、化学的に安定で薬剤（医薬有効成分）との反応性が抑制ないしは防止された製剤用核粒子を提供する。医薬有効成分を含む皮膜を表面に形成するための核粒子であって、（１）前記核粒子は、薬学的に許容される無機材料を含み、（２）前記無機材料が、水に対して難溶性であり、（３）前記無機材料の液性ｐＨが５～８である、ことを特徴とする製剤用核粒子に係る。  
PCT/JP2008/066159 2007-12-03 2008-09-08 製剤用核粒子 Ceased WO2009072334A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08857578.2A EP2223702B1 (en) 2007-12-03 2008-09-08 Core particle for pharmaceutical preparation
US12/745,851 US9149434B2 (en) 2007-12-03 2008-09-08 Core particle for pharmaceutical preparation
JP2009544605A JPWO2009072334A1 (ja) 2007-12-03 2008-09-08 製剤用核粒子

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007312894 2007-12-03
JP2007-312894 2007-12-03

Publications (1)

Publication Number Publication Date
WO2009072334A1 true WO2009072334A1 (ja) 2009-06-11

Family

ID=40717516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066159 Ceased WO2009072334A1 (ja) 2007-12-03 2008-09-08 製剤用核粒子

Country Status (4)

Country Link
US (1) US9149434B2 (ja)
EP (1) EP2223702B1 (ja)
JP (2) JPWO2009072334A1 (ja)
WO (1) WO2009072334A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011026307A (ja) * 2009-06-28 2011-02-10 Tomita Pharmaceutical Co Ltd 製剤用核粒子
JP2012508784A (ja) * 2008-11-14 2012-04-12 デブルジャ・ゼ・タソシエ・ファルマ γ−ヒドロキシ酪酸に基づく新規の組成物
WO2012091040A1 (ja) * 2010-12-27 2012-07-05 富田製薬株式会社 製剤用崩壊型核粒子

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
EP3860572B1 (en) 2018-10-04 2024-08-21 Chemische Fabrik Budenheim KG Spherical beads for use in producing pharmaceutically active pellets
EP3892262A1 (en) 2020-04-06 2021-10-13 Chemische Fabrik Budenheim KG Beads comprising a buffer system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0249728A (ja) * 1988-05-30 1990-02-20 Zeria Pharmaceut Co Ltd ジヒドロピリジン化合物の製剤組成物
JPH02258719A (ja) * 1989-03-30 1990-10-19 Taisho Pharmaceut Co Ltd 粒剤の製造方法
JPH0549901A (ja) * 1991-08-21 1993-03-02 Powrex:Kk 造粒方法
JP2003137771A (ja) * 2001-10-30 2003-05-14 Nichiko Pharmaceutical Co Ltd 難溶性薬物用医薬製剤
WO2006023286A2 (en) * 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51104026A (en) * 1975-03-05 1976-09-14 Ishii Hideki Arufua pp kurorufuenokishiisorakusanechiruganjukokeizaino seizoho
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
JPH07106970B2 (ja) * 1986-06-06 1995-11-15 ライオン株式会社 研磨基材
JPH03219787A (ja) 1990-01-24 1991-09-27 Mitsubishi Electric Corp 多地点間静止画会議システム
JP2542122B2 (ja) 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
JP2820829B2 (ja) * 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JP3219787B2 (ja) 1991-05-28 2001-10-15 フロイント産業株式会社 球形粒子の製造方法
JP2576927B2 (ja) * 1992-05-15 1997-01-29 ファイザー製薬株式会社 細粒核
JPH06192113A (ja) * 1992-09-25 1994-07-12 Powrex:Kk 生薬類の造粒方法および固形製剤
JP3349535B2 (ja) 1993-01-12 2002-11-25 フロイント産業株式会社 球形顆粒の製造方法
JP2700141B2 (ja) * 1993-09-17 1998-01-19 富士化学工業株式会社 リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤
JPH09175999A (ja) * 1995-12-22 1997-07-08 Freunt Ind Co Ltd 球形顆粒およびその製造方法
JP3447042B2 (ja) * 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
JP3172695B2 (ja) * 1997-08-07 2001-06-04 ビーエーエスエフ アクチェンゲゼルシャフト 球形晶析法による直打用アスコルビン酸原末造粒物、その製造法およびそれを用いた錠剤
JPH11322588A (ja) * 1998-03-20 1999-11-24 Kowa Co 胃・十二指腸付着性医薬組成物
TW499394B (en) * 1998-04-24 2002-08-21 Fuji Chem Ind Co Ltd A saccaride-containing cpmposition
JP4358920B2 (ja) * 1998-10-07 2009-11-04 興和創薬株式会社 エリスリトール含有球形顆粒剤及びその製造方法
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DK1140027T3 (da) * 1998-12-23 2006-02-27 Alza Corp Doseringsformer indeholdende poröse partikler
GB0003782D0 (en) * 2000-02-17 2000-04-05 Dumex Ltd As Process

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0249728A (ja) * 1988-05-30 1990-02-20 Zeria Pharmaceut Co Ltd ジヒドロピリジン化合物の製剤組成物
JPH02258719A (ja) * 1989-03-30 1990-10-19 Taisho Pharmaceut Co Ltd 粒剤の製造方法
JPH0549901A (ja) * 1991-08-21 1993-03-02 Powrex:Kk 造粒方法
JP2003137771A (ja) * 2001-10-30 2003-05-14 Nichiko Pharmaceutical Co Ltd 難溶性薬物用医薬製剤
WO2006023286A2 (en) * 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2223702A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508784A (ja) * 2008-11-14 2012-04-12 デブルジャ・ゼ・タソシエ・ファルマ γ−ヒドロキシ酪酸に基づく新規の組成物
JP2011026307A (ja) * 2009-06-28 2011-02-10 Tomita Pharmaceutical Co Ltd 製剤用核粒子
WO2012091040A1 (ja) * 2010-12-27 2012-07-05 富田製薬株式会社 製剤用崩壊型核粒子
JP5578534B2 (ja) * 2010-12-27 2014-08-27 富田製薬株式会社 製剤用崩壊型核粒子
JP2014169318A (ja) * 2010-12-27 2014-09-18 Tomita Pharmaceutical Co Ltd 製剤用崩壊型核粒子

Also Published As

Publication number Publication date
EP2223702A1 (en) 2010-09-01
EP2223702A4 (en) 2013-10-02
JP2014196361A (ja) 2014-10-16
EP2223702B1 (en) 2019-05-08
US20100260856A1 (en) 2010-10-14
JPWO2009072334A1 (ja) 2011-04-21
JP5757492B2 (ja) 2015-07-29
US9149434B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
WO2009072334A1 (ja) 製剤用核粒子
WO2007109057A3 (en) Solid dosage form containing a taste masked active agent
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2008149440A1 (ja) 速溶性及び可撓性を有するフィルム製剤
WO2009061607A3 (en) Water-immiscible materials as vehicles for drug delivery
NZ778023A (en) Colonic drug delivery formulation
WO2007133583A3 (en) Zero-order modified release solid dosage forms
WO2007095600A3 (en) Disintegrable oral films
WO2007047948A3 (en) Intranasal administration of rapid acting insulin
WO2012054831A3 (en) Ready to use ketorolac formulations
UA100403C2 (en) Capsule formulation
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2011039768A3 (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
WO2009106824A3 (en) Pharmaceutical formulations with a taste masking coating
WO2007016388A3 (en) Liquid formulations for controlled delivery of benzisoxazole derivatives
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
CY1107576T1 (el) Ταχεια αποδεσμευση των υδατοδιαλυτων φαρμακευτικων ουσιων
WO2009016069A3 (en) Stable liquid pharmaceutical composition based on trazodone
WO2006060681A3 (en) Pharmaceutical composition containing an anti-nucleating agent
WO2005079750A3 (en) Films for use as dosage forms
WO2007144902A8 (en) Chewable bilayer tablet formulation
WO2007084212A3 (en) Biologically active composition comprising ethylcellulose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857578

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009544605

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12745851

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008857578

Country of ref document: EP